Printer Friendly

GYNEX BEGINS PHASE III TRIAL OF POTENTIAL NEW TESTOSTERONE THERAPY

 GYNEX BEGINS PHASE III TRIAL OF POTENTIAL NEW TESTOSTERONE THERAPY
 VERNON HILLS, Ill., Sept. 22 /PRNewswire/ -- Gynex Pharmaceuticals, Inc. (NASDAQ: GYNX) today announced it has begun a Phase III placebo- controlled clinical study of its drug Androtest-SL(TM) (sublingual or "under the tongue" testosterone) for the treatment of men with hypogonadism (low testosterone levels). An estimated 400,000 American men suffer from this condition, which is associated with impotence, decreased libido, insufficient muscle development, and bone loss. Androtest-SL(TM) is being studied as an alternative to current testosterone therapy: intramuscular injection.
 Gynex believes Androtest-SL(TM) would be preferable to injectable testosterone 1) because of its ease of administration and 2) because Androtest-SL(TM) may allow physicians to better individualize a patient's therapy (since it is given daily versus every two to three weeks for the injectable products). The study is being conducted by Ronald S. Swerdloff M.D., chief of endocrinology, at Harbor-UCLA Medical Center in Torrance, Calif., and Christina Wang, M.D., director, Andrology Service, Division of Endocrinology and Metabolism at Cedars- Sinai Medical Center in Los Angeles.
 OTHER POTENTIAL TESTOSTERONE USE
 Gynex also plans to study Androtest-SL(TM) as testosterone replacement therapy in older men. Testosterone production is known to decline as men age, and this may lead to conditions similar to hypognadism including a decrease in sexual function, reduced muscle mass and bone density, and an increase risk of osteoporosis. A number of government funded studies are being conducted by independent researchers to determine whether testosterone therapy can help alleviate these and other negative effects of aging. If the studies support testosterone use in men as they get older, Gynex believes these men would prefer taking testosterone therapy sublingually, as in Androtest-SL(TM), as opposed to injections twice a month. There currently are approximately 18 million American men over the age of 60.
 Gynex Pharmaceuticals, Inc., is a research-based pharmaceutical company that develops and markets products for use in endocrinology, urology, metabolism, AIDS and gynecology.
 -0- 9/22/92
 /CONTACT: Stephen Simes of Gynex Pharmaceuticals, 708-913-1144, or Lynne Franklin of the Financial Relations Board, 312-266-7800, for Gynex Pharmaceuticals/
 (GYNX) CO: Gynex Pharmaceuticals, Inc. ST: Illinois IN: MTC SU:


PS -- NY040 -- 2101 09/22/92 10:42 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 22, 1992
Words:370
Previous Article:IBM ANNOUNCES DISTRIBUTED TRANSACTION PROCESSING SOFTWARE, NEW MODELS, OTHER ENHANCEMENTS FOR ITS RISC SYSTEM/6000 FAMILY
Next Article:PROBE RESEARCH, INC., AND NEW NETWORKS INSTITUTE FORM JOINT VENTURE
Topics:


Related Articles
GYNEX BEGINS AIDS PATIENT TESTING OF POTENTIAL NEW DRUG THERAPY
GYNEX RECEIVES FDA APPROVAL OF TREATMENT IND FOR USE OF OXANDRIN(TM) IN GROWTH DISORDER
GYNEX PHARMACEUTICALS ANNOUNCES FIRST ORAL DRUG FOR TURNER SYNDROME
GYNEX DRUG CUTS DEATH RATE IN ALCOHOLIC HEPATITIS STUDY; GYNEX PLANS TO INCLUDE RESULTS IN FDA SUBMISSION BY THE END OF 1993
SMITHKLINE BEECHAM TO FILE 13 NEW CHEMICAL ENTITIES AND 8 VACCINES OVER THE NEXT 3 YEARS
Unimed Pharmaceuticals Initiates Phase III Geriatric Hypogonadism Study in Elderly Men
ATRIX REPORTS SUCCESSFUL RESULTS FOR PROSTATE CANCER TREATMENT.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters